Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Determining the origin of TP53 mutations in patients with mature B-cell neoplasms is essential to distinguish lymphoma-related mutations from those due to clonal hematopoiesis, helping to guide treatment decisions

Veronika Ecker, Wencke Walter, Martha-Lena Mueller, Nicola Goetz, Christiane Eder, Manja Meggendorfer, Sandra Huber, Jana Wobst, Wolfgang Kern, Gregor Hoermann

Blood (2025) 146 (Supplement 1): 5389.

https://doi.org/10.1182/blood-2025-5389

Published: 2025

Journal Articles

Non-invasive MDS diagnostic algorithm can also identify pre-MDS and distinguishes normal controls from MDS/pre-MDS patients without bone marrow examination

Howard Oster, Sandra Huber, Jacqueline Ferrari, Martina Boldini, Sara Pozzi, Chiara Elena, Catherine Cargo, Torsten Haferlach, Luca Malcovati, Moshe Mittelman

Blood (2025) 146 (Supplement 1): 5632.

https://doi.org/10.1182/blood-2025-5632

Published: 2025

Journal Articles

MDS without clonal marker: When depth outperforms breadth

Sandra Huber, Wencke Walter, Marietta Truger, Stephan Hutter, Heiko Mueller, Torsten Haferlach, Manja Meggendorfer

Blood (2025) 146 (Supplement 1): 2071.

https://doi.org/10.1182/blood-2025-2071

Published: 2025

Journal Articles

Additional genetic targets are present in the majority of AML patients with NPM1, KMT2A or NUP98 aberrations potentially impacting combination therapy with menin inhibitors

Rainer Ordemann, Sandra Huber, Alessandro Baldi, Anna Stengel, Irene Fuhrmann, Christian Pohlkamp, Manja Meggendorfer, Sabit Delic, Wolfgang Kern, Torsten Haferlach, Gregor Hoermann

Blood (2025) 146 (Supplement 1): 5248.

https://doi.org/10.1182/blood-2025-5248

Published: 2025

Journal Articles

The role of sole loss of chromosome y in myeloid neoplasms

Sandra Huber, Stephan Hutter, Manja Meggendorfer, Christian Pohlkamp, Torsten Haferlach, Isolde Summerer

Blood (2025) 146 (Supplement 1): 1390.

https://doi.org/10.1182/blood-2025-1390

Published: 2025

Journal Articles

Two Ways to Complex Karyotype in MDS - the Role of Del(5q) and TP53

Claudia Haferlach, Sandra Huber, Stephan Hutter, Constance Regina Baer, Manja Meggendorfer, Gregor Hoermann, Wolfgang Kern, Torsten Haferlach

Blood (2024) 144 (Supplement 1): 1836.

https://doi.org/10.1182/blood-2024-201270

Published: 2024

Journal Articles

Similarities and Differences of DNMT3A , TET2 and ASXL1 Mutations across Ccus, MDS and AML

Sandra Huber, Stephan Hutter, Constance Regina Baer, Manja Meggendorfer, Gregor Hoermann, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach

Blood (2024) 144 (Supplement 1): 1819.

https://doi.org/10.1182/blood-2024-200561

Published: 2024

Journal Articles

Phenotypic and Genetic Heterogeneity of NPM1 Mutated AML at Diagnosis and during Course of Disease

Veronika Ecker, Sandra Huber, Wencke Walter, Stephan Hutter, Martha-Lena Mueller, Manja Meggendorfer, Constance Regina Baer, Claudia Haferlach, Torsten Haferlach, Wolfgang Kern

Blood (2024) 144 (Supplement 1): 6118.

https://doi.org/10.1182/blood-2024-209675

Published: 2024

Journal Articles

The Frequency of Clonal Hematopoiesis Prior to AML and MDS Varies Among the Different Molecularly Defined Who Subtypes

Constance Regina Baer, Sandra Huber, Gregor Hoermann, Manja Meggendorfer, Stephan Hutter, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach

Blood (2023) 142 (Supplement 1): 725.

https://doi.org/10.1182/blood-2023-179737

Published: 2023

Journal Articles

Classification of Philadelphia-Negative MPN As Low Risk and High Risk MPN Based on Peripheral Blood Values and Molecular Genetics Only

Sandra Huber, Gregor Hoermann, Manja Meggendorfer, Stephan Hutter, Constance Regina Baer, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach

Blood (2023) 142 (Supplement 1): 3184.

https://doi.org/10.1182/blood-2023-174872

Published: 2023

Journal Articles

Modification of the ELN Classification 2022 Refines Risk Assessment in MDS/AML Patients

Sandra Huber, Constance Regina Baer, Stephan Hutter, Frank Dicker, Irene Fuhrmann, Manja Meggendorfer, Christian Pohlkamp, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach, Gregor Hoermann

Blood (2023) 142 (Supplement 1): 61.

https://doi.org/10.1182/blood-2023-179822

Published: 2023

Journal Articles

A Proposal for a Classification of Ccus, MDS and AML Primarily Based on Genetic Abnormalities Considering the Biological Continuum of These Entities

Claudia Haferlach, Sandra Huber, Constance Regina Baer, Stephan Hutter, Manja Meggendorfer, Wolfgang Kern, Gregor Hoermann, Torsten Haferlach

Blood (2023) 142 (Supplement 1): 6492.

https://doi.org/10.1182/blood-2023-179188

Published: 2023

Journal Articles

Whole Genome and Transcriptome Sequencing of 21 Paired Chronic and Blast Phase CML Cases: Acquisition of Genomic Alterations, Changes in the Transcriptomic Profiles and Occurrence of B-Cell Receptor Rearrangements

Claudia Haferlach, Wencke Walter, Heiko Mueller, Sandra Huber, Constance Regina Baer, Stephan Hutter, Manja Meggendorfer, Gregor Hoermann, Wolfgang Kern, Torsten Haferlach

Blood (2023) 142 (Supplement 1): 3170.

https://doi.org/10.1182/blood-2023-185867

Published: 2023

Journal Articles

Genomic Landscape of Ccus Compared to MDS Indicates a Potential Applicability of the IPSS-M

Sandra Huber, Constance Regina Baer, Stephan Hutter, Gregor Hoermann, Christian Pohlkamp, Wencke Walter, Manja Meggendorfer, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach

Blood (2023) 142 (Supplement 1): 4609.

https://doi.org/10.1182/blood-2023-177582

Published: 2023

Journal Articles

Parallel Genomic Analysis from Paired Bone Marrow and Peripheral Blood Samples of 200 Cytopenic Patients

Sandra Huber, Natalie Wossidlo, Torsten Haferlach, Manja Meggendorfer, Stephan Hutter, Gregor Hoermann, Isolde Summerer, Henning Ruge, Constance Regina Baer, Wolfgang Kern, Claudia Haferlach

Blood (2023) 142 (Supplement 1): 198.

https://doi.org/10.1182/blood-2023-174843

Published: 2023

Journal Articles

MDS Classification - Do We Still Have to Count Blasts?

Claudia Haferlach, Sandra Huber, Heiko Mueller, Constance Baer, Gregor Hoermann, Manja Meggendorfer, Stephan Hutter, Wolfgang Kern, Torsten Haferlach

Blood (2022) 140 (Supplement 1): 1130–1131.

https://doi.org/10.1182/blood-2022-162147

Published: 2022

Journal Articles

Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools

Constance Baer, Sandra Huber, Stephan Hutter, Manja Meggendorfer, Niroshan Nadarajah, Wencke Walter, Uwe Platzbecker, Katharina Götze, Wolfgang Kern, Torsten Haferlach, Gregor Hoermann, Claudia Haferlach

Blood (2022) 140 (Supplement 1): 1128–1129.

https://doi.org/10.1182/blood-2022-159939

Published: 2022

Journal Articles

AML and MDS Classification According to Who 2022 and International Consensus Classification: Do We Invent a Babylonian Confusion of Languages?

Sandra Huber, Constance Baer, Stephan Hutter, Frank Dicker, Manja Meggendorfer, Christian Pohlkamp, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach, Gregor Hoermann

Blood (2022) 140 (Supplement 1): 555–556.

https://doi.org/10.1182/blood-2022-162326

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Determining the origin of TP53 mutations in patients with mature B-cell neoplasms is essential to distinguish lymphoma-related mutations from those due to clonal hematopoiesis, helping to guide treatment decisions

Non-invasive MDS diagnostic algorithm can also identify pre-MDS and distinguishes normal controls from MDS/pre-MDS patients without bone marrow examination

MDS without clonal marker: When depth outperforms breadth

Additional genetic targets are present in the majority of AML patients with NPM1, KMT2A or NUP98 aberrations potentially impacting combination therapy with menin inhibitors

The role of sole loss of chromosome y in myeloid neoplasms

Two Ways to Complex Karyotype in MDS - the Role of Del(5q) and TP53

Similarities and Differences of DNMT3A , TET2 and ASXL1 Mutations across Ccus, MDS and AML

Phenotypic and Genetic Heterogeneity of NPM1 Mutated AML at Diagnosis and during Course of Disease

The Frequency of Clonal Hematopoiesis Prior to AML and MDS Varies Among the Different Molecularly Defined Who Subtypes

Classification of Philadelphia-Negative MPN As Low Risk and High Risk MPN Based on Peripheral Blood Values and Molecular Genetics Only

Modification of the ELN Classification 2022 Refines Risk Assessment in MDS/AML Patients

A Proposal for a Classification of Ccus, MDS and AML Primarily Based on Genetic Abnormalities Considering the Biological Continuum of These Entities

Whole Genome and Transcriptome Sequencing of 21 Paired Chronic and Blast Phase CML Cases: Acquisition of Genomic Alterations, Changes in the Transcriptomic Profiles and Occurrence of B-Cell Receptor Rearrangements

Genomic Landscape of Ccus Compared to MDS Indicates a Potential Applicability of the IPSS-M

Parallel Genomic Analysis from Paired Bone Marrow and Peripheral Blood Samples of 200 Cytopenic Patients

MDS Classification - Do We Still Have to Count Blasts?

Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools

AML and MDS Classification According to Who 2022 and International Consensus Classification: Do We Invent a Babylonian Confusion of Languages?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only